Visioneering Technologies, Inc.

Equities

VTI

AU000000VTI2

Medical Equipment, Supplies & Distribution

Delayed Australian S.E. Other stock markets 10:24:35 2024-04-22 pm EDT			5-day change	1st Jan Change
0.175 ^AUD	+9.38%		0.00%	-30.00%

Feb. 28	Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study	MT

Visioneering Technologies, Inc. Announces Retirement of Tom Dooley as a Non-Executive Director

June 07, 2021 at 10:28 pm EDT

Visioneering Technologies, Inc. announced the retirement of Mr. Tom Dooley as a non-executive director of the Company, effective June 8, 2021, immediately following the closing of the Annual Meeting of Stockholders.

Latest news about Visioneering Technologies, Inc.

Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Visioneering Technologies Releases One-Year Data from Myopia Progression Control Study	Jan. 18	MT
Visioneering Technologies Issues Part of Shortfall from Rights Offering	Jan. 04	MT
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	Nov. 01
Transcript : Visioneering Technologies, Inc., Q3 2023 Earnings Call, Oct 18, 2023	23-10-18
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion	23-10-10	MT
Visioneering Technologies Appoints CEO	23-08-28	MT
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Chief Executive Officer, Effective 1 October 2023	23-08-28	CI
Visioneering Technologies, Inc. Announces the Appointment of Juan Carlos Aragón as Executive Director, Effective 1 October 2023	23-08-28	CI
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Transcript : Visioneering Technologies, Inc., Q2 2023 Earnings Call, Jul 21, 2023	23-07-20
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	23-05-24
Transcript : Visioneering Technologies, Inc., Q1 2023 Earnings Call, Apr 20, 2023	23-04-19
Visioneering Technologies Says Exposure to Collapsed Silicon Valley Bank is Minimal	23-03-12	MT
Visioneering Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Visioneering Technologies, Inc. Announces Board Changes	22-12-19	CI
Visioneering Technologies Hits 100% Enrollment Milestone for NaturalVue Multifocal Contact Lens Trial	22-12-07	MT
Visioneering Technologies, Inc. Enrolls 100% of Subjects in its International Randomized Controlled Clinical Trial Known as PROTECT	22-12-06	CI
Transcript : Visioneering Technologies, Inc. - Shareholder/Analyst Call	22-10-26
Visioneering Technologies, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-22	CI
Transcript : Visioneering Technologies, Inc., Q2 2022 Earnings Call, Jul 20, 2022	22-07-20
Visioneering Technologies Reaches 50% Enrolment Milestone in Nearsightedness Clinical Trial	22-07-12	MT
Visioneering Technologies, Inc. Achieves 50% Enrollment Milestone in its PROTECT International Clinical Study for Myopia Progression Control	22-07-12	CI
Visioneering Technologies, Inc. Announces Board Changes	22-06-29	CI
Visioneering Technologies, Inc. Provides Revenue Guidance for the Year 2022	22-06-02	CI

Chart Visioneering Technologies, Inc.

Duration

Period

More charts

Company Profile

Visioneering Technologies, Inc. is a medical device company. The Company is primarily engaged in the design, manufacture, sale and distribution of a contact lens, the NaturalVue Multifocal 1 Day (NaturalVue MF) contact lens. The Company operates through two segments: North America and Europe / Asia-Pacific. The North America segment includes its operations in the United States and Canada. The Europe/Asia-Pacific segment includes its operations outside of North America. Its flagship product is the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lens for adults with Presbyopia and children with Myopia. The Company sells its contact lenses in the United States, Europe, Australia, New Zealand, Hong Kong, Singapore, Canada and Malaysia. The Company manages the warehousing and distribution of its products through a contract with a third-party logistics provider (the 3PL).

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-23 - March 2024 Sales and Revenue Call - Activities Report

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Glasses, Spectacles & Contact Lenses

	1st Jan change	Capi.
VISIONEERING TECHNOLOGIES, INC.	-30.00%	5.68M
ESSILORLUXOTTICA	+12.78%	97.69B
ALCON INC.	+12.40%	39.6B
THE COOPER COMPANIES, INC.	-3.10%	17.9B
AUTEK CHINA INC.	-23.03%	2.12B
WARBY PARKER INC.	-4.96%	1.46B
PEGAVISION CORPORATION	+21.69%	1.09B
MINGYUE OPTICAL LENS CO.,LTD.	-38.53%	759M
MENICON CO., LTD.	-36.57%	740M
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.	-12.09%	613M

Glasses, Spectacles & Contact Lenses